NO20012351L - Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel - Google Patents

Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel

Info

Publication number
NO20012351L
NO20012351L NO20012351A NO20012351A NO20012351L NO 20012351 L NO20012351 L NO 20012351L NO 20012351 A NO20012351 A NO 20012351A NO 20012351 A NO20012351 A NO 20012351A NO 20012351 L NO20012351 L NO 20012351L
Authority
NO
Norway
Prior art keywords
sensitizing agent
pharmaceutical composition
modified release
insulin sensitizing
composition
Prior art date
Application number
NO20012351A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012351D0 (no
Inventor
Robert Glinecke
William Muldoon
Joseph Sauer
Susan Marie Milosovich
Vincenzo Re
Janet Louise Skinner
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO20012351D0 publication Critical patent/NO20012351D0/no
Publication of NO20012351L publication Critical patent/NO20012351L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20012351A 1998-11-12 2001-05-11 Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel NO20012351L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use
PCT/EP1999/009031 WO2000028990A1 (fr) 1998-11-12 1999-11-12 Composition pharmaceutique de sensibilisateur modifiant la liberation d'insuline

Publications (2)

Publication Number Publication Date
NO20012351D0 NO20012351D0 (no) 2001-05-11
NO20012351L true NO20012351L (no) 2001-07-04

Family

ID=26314667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012351A NO20012351L (no) 1998-11-12 2001-05-11 Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel

Country Status (39)

Country Link
EP (3) EP1128827B1 (fr)
JP (1) JP2002529505A (fr)
KR (2) KR100732599B1 (fr)
CN (1) CN1289081C (fr)
AP (2) AP2008004490A0 (fr)
AR (2) AR023700A1 (fr)
AT (1) ATE382352T1 (fr)
AU (1) AU768578B2 (fr)
BG (2) BG109893A (fr)
BR (1) BR9915215A (fr)
CA (1) CA2350659C (fr)
CO (1) CO5190673A1 (fr)
CY (1) CY1107909T1 (fr)
CZ (1) CZ20011628A3 (fr)
DE (1) DE69937898T2 (fr)
DK (1) DK1128827T3 (fr)
DZ (1) DZ2937A1 (fr)
EA (3) EA200601144A1 (fr)
EG (2) EG24463A (fr)
ES (1) ES2299269T3 (fr)
HK (1) HK1040909B (fr)
HR (2) HRP20010342B1 (fr)
HU (1) HUP0104307A3 (fr)
ID (1) ID29344A (fr)
IL (2) IL143003A0 (fr)
MY (1) MY135973A (fr)
NO (1) NO20012351L (fr)
NZ (2) NZ511611A (fr)
OA (1) OA11676A (fr)
PE (1) PE20001428A1 (fr)
PL (1) PL198717B1 (fr)
PT (1) PT1128827E (fr)
RS (1) RS50208B (fr)
SI (1) SI1128827T1 (fr)
SK (1) SK286937B6 (fr)
TR (2) TR200101337T2 (fr)
TW (2) TWI257305B (fr)
UY (2) UY25798A1 (fr)
WO (1) WO2000028990A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2004504264A (ja) * 2000-01-07 2004-02-12 ユニバーシティ　オブ　シンシナティ Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化
WO2002060415A1 (fr) * 2001-01-31 2002-08-08 Röhm GmbH & Co. KG Forme galenique multiparticulaire contenant au moins deux formes de pellets enrobes de differentes manieres
JP2005514399A (ja) * 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
EP1552832A1 (fr) * 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
EP1589951B1 (fr) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Utilisation d'un melange de deux ou de plusieurs materiaux enteriques afin de reguler la liberation de medicaments via une membrane ou une matrice dans des therapies systemiques
EP1588708A4 (fr) 2003-01-29 2006-03-01 Takeda Pharmaceutical Procede pour realiser une preparation enrobee
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
CN103945832B (zh) * 2011-07-14 2017-03-29 能脑有限责任公司 用于脑能量分子延迟释放和持续释放的组合物，装置及方法
CA2936748C (fr) 2014-10-31 2017-08-08 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Agents hypoglycemiques de thiazolidinedione
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (fr) 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0533933A4 (en) 1990-07-03 1993-05-05 Yamanouchi Pharmaceutical Co. Ltd. Bisheterocyclic compound
HUT70153A (en) 1990-08-23 1995-09-28 Pfizer Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
CA2106967C (fr) 1991-04-11 2003-12-09 Takashi Sohda Derives thiazolidinedione, leur production et leur utilisation
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (fr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (fr) 1992-04-10 1993-10-28 Smithkline Beecham Plc Composes heterocycliques et leur utilisation pour le traitement du diabete du type ii
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
JPH07508747A (ja) 1992-07-03 1995-09-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 医薬用複素環化合物
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
IL132032A0 (en) * 1997-03-24 2001-03-19 Galderma Res & Dev Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
AR023700A1 (es) 2002-09-04
DK1128827T3 (da) 2008-04-28
TR200503846T2 (tr) 2007-01-22
HRP20010342B1 (en) 2008-04-30
PT1128827E (pt) 2008-03-10
BG109893A (bg) 2008-11-28
NZ526440A (en) 2005-01-28
ES2299269T3 (es) 2008-05-16
EP1815855A1 (fr) 2007-08-08
HUP0104307A3 (en) 2003-12-29
UY25798A1 (es) 2000-12-29
CN1333683A (zh) 2002-01-30
EA200100540A1 (ru) 2001-10-22
SI1128827T1 (sl) 2008-06-30
TW200505436A (en) 2005-02-16
EP1128827B1 (fr) 2008-01-02
AU1272900A (en) 2000-06-05
DE69937898T2 (de) 2009-01-02
TWI246920B (en) 2006-01-11
HRP20080117A2 (en) 2008-10-31
EP1128827A1 (fr) 2001-09-05
CA2350659C (fr) 2009-06-09
SK286937B6 (sk) 2009-07-06
EA007608B1 (ru) 2006-12-29
NO20012351D0 (no) 2001-05-11
HK1040909A1 (en) 2002-06-28
EG24463A (en) 2009-07-16
HRP20010342A2 (en) 2002-06-30
MY135973A (en) 2008-07-31
KR100732599B1 (ko) 2007-06-27
EG22344A (en) 2002-12-31
IL183972A0 (en) 2007-10-31
ID29344A (id) 2001-08-23
PE20001428A1 (es) 2001-02-08
KR20010073229A (ko) 2001-07-31
EA200702648A1 (ru) 2008-10-30
WO2000028990A1 (fr) 2000-05-25
CY1107909T1 (el) 2013-09-04
ATE382352T1 (de) 2008-01-15
CN1289081C (zh) 2006-12-13
EA200601144A1 (ru) 2007-02-27
AR023699A1 (es) 2002-09-04
CO5190673A1 (es) 2002-08-29
TR200101337T2 (tr) 2001-11-21
EP1917962A1 (fr) 2008-05-07
BR9915215A (pt) 2001-07-31
YU36401A (sh) 2004-05-12
DE69937898D1 (de) 2008-02-14
IL143003A0 (en) 2002-04-21
SK6432001A3 (en) 2001-12-03
AP1901A (en) 2008-10-24
CA2350659A1 (fr) 2000-05-25
JP2002529505A (ja) 2002-09-10
AP2008004490A0 (en) 2008-06-30
KR20060097140A (ko) 2006-09-13
DZ2937A1 (fr) 2004-03-15
UY25800A1 (es) 2000-08-21
NZ511611A (en) 2003-10-31
HUP0104307A2 (hu) 2002-07-29
TWI257305B (en) 2006-07-01
PL348153A1 (en) 2002-05-06
BG65444B1 (bg) 2008-08-29
BG105570A (en) 2002-02-28
AU768578B2 (en) 2003-12-18
RS50208B (sr) 2009-07-15
HK1040909B (zh) 2008-08-01
OA11676A (en) 2005-01-12
PL198717B1 (pl) 2008-07-31
CZ20011628A3 (cs) 2001-12-12

Similar Documents

Publication Publication Date Title
CY1108587T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη απελευθερωση ενος ευαισθητοποιητη ινσουλινης και μετφορμινης
NO20012351L (no) Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
NO20011471L (no) Nye orale vedvarende frigivelsesformuleringer
BR0012901A (pt) Medicamentos de ß - carbolina
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE292453T1 (de) Antivirale arznei
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR019331A2 (es) Composicion farmaceutica que contiene un sensibilizador a insulina y un secretagogo de insulina.
DK0615439T3 (da) Iburprofenholdigt retard-lægemiddel og dets anvendelse
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
BR0312333A (pt) Terapia de combinação e agente para sua execução
ECSP993216A (es) Nueva composicion y uso ii
ES2179029T3 (es) Derivados de 14,15-alfa-metileno-equilenina, proceso para su preparacion y medicamentos que contienen los mismos.
UA38697A (uk) Спосіб лікування генералізованого пародонтиту
ECSP993215A (es) Nueva composicion y uso

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application